EXELIXIS INC (1EXEL.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1EXEL - US30161Q1040 - Common Stock
30.7 EUR
-2.85 (-8.49%)
Taking everything into account, 1EXEL scores 8 out of 10 in our fundamental rating. 1EXEL was compared to 83 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1EXEL a very profitable company, without any liquidiy or solvency issues. 1EXEL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make 1EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year 1EXEL was profitable.
In the past year 1EXEL had a positive cash flow from operations.
1EXEL had positive earnings in each of the past 5 years.
In the past 5 years 1EXEL always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 22.49%, 1EXEL belongs to the top of the industry, outperforming 91.89% of the companies in the same industry.
With an excellent Return On Equity value of 29.62%, 1EXEL belongs to the best of the industry, outperforming 90.54% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 25.22%, 1EXEL belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
1EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is in line with the industry average of 12.28%.
The last Return On Invested Capital (25.22%) for 1EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROIC | 25.22% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
1EXEL's Profit Margin of 27.01% is amongst the best of the industry. 1EXEL outperforms 86.49% of its industry peers.
In the last couple of years the Profit Margin of 1EXEL has declined.
With an excellent Operating Margin value of 33.71%, 1EXEL belongs to the best of the industry, outperforming 90.54% of the companies in the same industry.
In the last couple of years the Operating Margin of 1EXEL has declined.
1EXEL has a Gross Margin of 96.59%. This is amongst the best in the industry. 1EXEL outperforms 94.59% of its industry peers.
1EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
1EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
1EXEL has less shares outstanding than it did 1 year ago.
1EXEL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for 1EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 10.91 indicates that 1EXEL is not in any danger for bankruptcy at the moment.
1EXEL has a better Altman-Z score (10.91) than 86.49% of its industry peers.
1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 10.91 |
ROIC/WACC2.88
WACC8.75%
2.3 Liquidity
1EXEL has a Current Ratio of 3.51. This indicates that 1EXEL is financially healthy and has no problem in meeting its short term obligations.
1EXEL's Current ratio of 3.51 is fine compared to the rest of the industry. 1EXEL outperforms 68.92% of its industry peers.
1EXEL has a Quick Ratio of 3.44. This indicates that 1EXEL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 1EXEL (3.44) is better than 68.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 67.74% over the past year.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
The Revenue has grown by 10.73% in the past year. This is quite good.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
3.2 Future
The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth
Based on estimates for the next years, 1EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.06, which indicates a rather expensive current valuation of 1EXEL.
1EXEL's Price/Earnings ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 85.14% of the companies in the same industry.
1EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.38.
Based on the Price/Forward Earnings ratio of 12.20, the valuation of 1EXEL can be described as correct.
93.24% of the companies in the same industry are more expensive than 1EXEL, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.83. 1EXEL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 12.2 |
4.2 Price Multiples
1EXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 85.14% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1EXEL indicates a rather cheap valuation: 1EXEL is cheaper than 91.89% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.66 | ||
| EV/EBITDA | 10.4 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of 1EXEL may justify a higher PE ratio.
1EXEL's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.58
PEG (5Y)1.35
EPS Next 2Y25.34%
EPS Next 3Y25.84%
5. Dividend
5.1 Amount
No dividends for 1EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1EXEL (10/22/2025, 7:00:00 PM)
30.7
-2.85 (-8.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.89%
Inst Owner ChangeN/A
Ins Owners2.23%
Ins Owner ChangeN/A
Market Cap8.26B
Revenue(TTM)2.23B
Net Income(TTM)602.30M
Analysts76.92
Price Target38.31 (24.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)3.36%
EPS NY rev (1m)1.43%
EPS NY rev (3m)4.85%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.06 | ||
| Fwd PE | 12.2 | ||
| P/S | 4.28 | ||
| P/FCF | 12.66 | ||
| P/OCF | 12.37 | ||
| P/B | 4.7 | ||
| P/tB | 4.85 | ||
| EV/EBITDA | 10.4 |
EPS(TTM)1.8
EY5.86%
EPS(NY)2.52
Fwd EY8.19%
FCF(TTM)2.42
FCFY7.9%
OCF(TTM)2.48
OCFY8.09%
SpS7.17
BVpS6.54
TBVpS6.33
PEG (NY)0.58
PEG (5Y)1.35
Graham Number16.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| ROCE | 32.1% | ||
| ROIC | 25.22% | ||
| ROICexc | 38.09% | ||
| ROICexgc | 39.72% | ||
| OM | 33.71% | ||
| PM (TTM) | 27.01% | ||
| GM | 96.59% | ||
| FCFM | 33.81% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 60.32% | ||
| Cap/Sales | 0.81% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.79% | ||
| Profit Quality | 125.2% | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 10.91 |
F-Score8
WACC8.75%
ROIC/WACC2.88
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y29.59%
EPS Next 2Y25.34%
EPS Next 3Y25.84%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.2%
Revenue Next 2Y9.86%
Revenue Next 3Y11.44%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5YN/A
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / 1EXEL.MI FAQ
Can you provide the ChartMill fundamental rating for EXELIXIS INC?
ChartMill assigns a fundamental rating of 8 / 10 to 1EXEL.MI.
What is the valuation status for 1EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (1EXEL.MI). This can be considered as Undervalued.
How profitable is EXELIXIS INC (1EXEL.MI) stock?
EXELIXIS INC (1EXEL.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for 1EXEL stock?
The financial health rating of EXELIXIS INC (1EXEL.MI) is 9 / 10.
Can you provide the expected EPS growth for 1EXEL stock?
The Earnings per Share (EPS) of EXELIXIS INC (1EXEL.MI) is expected to grow by 29.59% in the next year.